In This Article:
Vivoryon Therapeutics N.V. Announces Planned Changes to Board Composition at 2023 Annual General Meeting
Halle (Saale) / Munich, Germany, May 1, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced intended changes among the Non-Executive members of its Board of Directors at Vivoryon’s 2023 Annual General Meeting to be held later this year.
Reflecting Vivoryon’s continued progress towards becoming a late-stage clinical development company and in line with the Company’s commitment to meeting international best-practice standards for corporate governance and diversity, the two long-standing members Dinnies Johannes von der Osten, PhD, and Jörg Neermann, PhD, have decided in agreement with the Company to step down at the 2023 Annual General Meeting. Vivoryon intends to propose the appointment of one or two new Non-Executive Board members, with the objective of the Board’s composition better reflecting the Company’s current shareholder structure and strategic growth opportunities.
“On behalf of the Board of Directors and the entire Vivoryon team, I would like to thank Dinnies von der Osten and Jörg Neermann for their valuable contributions over the years,” said Erich Platzer, MD, Chairman of the Board of Directors of Vivoryon. “In over a decade of service, they helped to guide the Company through many stages of development. I sincerely wish them all the best in their future endeavors. I look forward to providing an update on the proposed Board additions in the context of our AGM.”
The full agenda for the 2023 Annual General Meeting will be published on Vivoryon’s website in May 2023.
###
About Vivoryon Therapeutics N.V.
Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines. Driven by our passion for ground-breaking science and innovation, we strive to change the lives of patients in need suffering from severe diseases. We leverage our in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. Beyond our lead program, varoglutamstat, which is in Phase 2 clinical development to treat Alzheimer’s disease, we have established a solid pipeline of orally available small molecule inhibitors for various indications including cancer, inflammatory diseases and fibrosis. www.vivoryon.com